Revenue Reaches 247.3 Billion Won, Up 8% Year-on-Year

Operating Profit Down 15% Compared to Previous Year

Medytox announced on March 12 that its consolidated revenue for the previous year reached 247.3 billion won, marking an 8% increase compared to the prior year.


During the same period, operating profit dropped by 15% to 17.2 billion won, and net profit declined by 4% to 15.5 billion won.

Medytox Global Business Center. Medytox

Medytox Global Business Center. Medytox

View original image

Medytox stated, “The strong performance of our core business—botulinum toxin products—drove the revenue growth, allowing us to achieve record-high annual sales for the third consecutive year. However, operating profit and net profit decreased compared to the previous year, primarily due to increased selling and administrative expenses, as well as business restructuring measures such as the disposal of subsidiaries.”


Specifically, total revenue from the toxin segment grew by 25% year-on-year, leading the company’s overall sales growth. In the domestic premium toxin market, the company’s ‘Coretox’ solidified its position, while the next-generation botulinum toxin product ‘Neulux’ expanded its overseas presence, contributing to higher sales. Meanwhile, revenue from the filler segment declined by 5% compared to the previous year.


This year, Medytox plans to focus on the launch of ‘Newviju,’ a submental fat reduction injection that has obtained approval as the 40th domestically developed new drug, and on the rapid market entry of ‘MT961,’ a probiotic for body fat reduction, in the health functional food sector.



A Medytox representative stated, “We expect that new products scheduled for release in the first half of the year will have a positive impact on our medium- and long-term performance. Moving forward, we will continue to strengthen our competitiveness in the global aesthetics market through ongoing research and development and diversification of our product portfolio.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing